CD8A and systemic lupus erythematosus: To enhance the specificity of our drug repurposing approach, leveraging the iLINCS, CLUE and L1000CDS2 platforms, we identified the 50 top-ranked compounds, that could reverse the publicly available transcriptional signatures of circulating CD4+ [56], CD8+-T [56] and B-cells [57] obtained from SLE patients and we determined the agents that were exclusively related to the monocytes (Fig. 1B).